Investerinsgforeningen Nykredit Invest Balance suspenderer handel med alle afdelinger
Nykredit Portefølje Administration A/S har anmodet Nasdaq Copenhagen om suspension af alle afdelinger, som administreres af Nykredit Portefølje Administration A/S. Det skyldes, at det grundet tekniske problemer ikke er muligt at stille NAV for disse fonde.
Suspensionen vil blive ophævet, når det igen er muligt at stille korrekte priser.
Det drejer sig om følgende fonde:
| ISIN Cur | Afdeling | Orderbook Code Cur |
| DK0016188733 | Nykredit Invest Balance Defensiv KL | NBIDE |
| DK0016188816 | Nykredit Invest Balance Moderat KL | NBIMO |
| DK0060441749 | Nykredit Invest Balance Offensiv KL | NBIOF |
Eventuelle spørgsmål vedrørende denne meddelelse kan rettes til npa.pm@nykredit.dk eller JNA@nykredit.dk
Med venlig hilsen
Nykredit Portefølje Administration A/S
Tage Fabrin-Brasted
To view this piece of content from www.globenewswire.com, please give your consent at the top of this page.To view this piece of content from ml-eu.globenewswire.com, please give your consent at the top of this page.
About GlobeNewswire by notified
GlobeNewswire by notifiedGlobeNewswire by notified is one of the world's largest newswire distribution networks, specializing in the delivery of corporate press releases financial disclosures and multimedia content to the media, investment community, individual investors and the general public.
Subscribe to releases from GlobeNewswire by notified
Subscribe to all the latest releases from GlobeNewswire by notified by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from GlobeNewswire by notified
DSV, 1103 - INTERIM FINANCIAL REPORT Q1 202424.4.2024 07:30:53 CEST | Press release
Company Announcement No. 1103 Selected key figures and ratios for the period 1 January – 31 March 2024 Q1 2024Q1 2023Key figures (DKKm)Revenue38,34040,954Gross profit10,26511,391Operating profit (EBIT) before special items3,6414,672Profit for the period2,3933,287Adjusted earnings for the period2,4633,340RatiosConversion ratio35.5%41.0%Diluted adjusted earnings per share of DKK 1 for the last 12 months55.376.9 Jens H. Lund, Group CEO: “In a normalising market, we are off to a good start delivering strong financial results in the first quarter of 2024, and I am particularly satisfied that we are gaining market shares in all three divisions. We have also completed the leadership changes, the organisation has settled, and together with the new and experienced leadership team we will concentrate our efforts on executing on our strategy, with particular focus on our customers.” Outlook for 2024 We maintain our outlook for 2024 as announced in the 2023 Annual Report: Operating profit (EBIT) b
Ringkjøbing Landbobanks kvartalsrapport for 1. kvartal 202424.4.2024 07:30:00 CEST | pressemeddelelse
Nasdaq Copenhagen London Stock Exchange Euronext Dublin Øvrige interessenter 24. april 2024 Ringkjøbing Landbobanks kvartalsrapport for 1. kvartal 2024 Bankens bestyrelse og direktion har i dag godkendt kvartalsrapporten for 1. kvartal 2024. Banken realiserer i årets første kvartal et basisresultat på 793 mio. kroner og et resultat efter skat på 616 mio. kroner. Resultatet efter skat forrenter egenkapitalen med 24% p.a. Basisresultat (mio. kroner)1. kvartal 20241. kvartal 20232023202220212020Basisindtjening i alt1.0408493.8282.8622.4332.179Samlede udgifter og afskrivninger247227963891817788Basisresultat før nedskrivninger på udlån7936222.8651.9711.6161.391Nedskrivninger på udlån m.v.0-1-1-2-68-223Basisresultat7936212.8641.9691.5481.168Beholdningsresultat m.v.+23-21-7-69+7-9Af- og nedskrivninger på immaterielle aktiver5520201715Skat195140682385309224Resultat efter skat6164552.1551.4951.229920 1. kvartal 2024 i overskrifter Resultatet efter skat udgør 616 mio. kroner, hvilket forrenter e
Ringkjøbing Landbobank’s quarterly report for the first quarter of 202424.4.2024 07:30:00 CEST | Press release
Nasdaq Copenhagen London Stock Exchange Euronext Dublin Other stakeholders 24 April 2024 Ringkjøbing Landbobank’s quarterly report for the first quarter of 2024 The bank’s board of directors and general management today approved the quarterly report for the first quarter of 2024. The bank delivers core earnings of DKK 793 million and net profit of DKK 616 million in the first quarter of the year. The net profit is equivalent to a 24% p.a. return on equity. Core earnings (DKK million)Q1 2024Q1 20232023202220212020Total core income1,0408493,8282,8622,4332,179Total expenses and depreciation247227963891817788Core earnings before impairment charges for loans7936222,8651,9711,6161,391Impairment charges for loans etc.0-1-1-2-68-223Core earnings7936212,8641,9691,5481,168Result for the portfolio etc.+23-21-7-69+7-9Amortisation and write-downs on intangible assets5520201715Tax195140682385309224Net profit6164552,1551,4951,229920 Highlights of the first quarter of 2024 The net profit is DKK 616 mi
Borregaard ASA: EBITDA1 of NOK 442 million in the 1st quarter24.4.2024 07:00:00 CEST | Press release
Borregaard’s operating revenues reached NOK 1,975 million (NOK 1,850 million)2 in the 1st quarter of 2024. EBITDA1 increased to NOK 442 million (NOK 435 million). The result in BioSolutions increased while results in BioMaterials and Fine Chemicals were lower compared with the 1st quarter of 2023. The result in BioSolutions increased due to higher sales volume and reduced energy costs. In BioMaterials, higher sales volume was more than offset by lower sales prices and higher wood costs. Fine Chemicals had a lower result due to low bioethanol deliveries and increased costs. The net currency effects were slightly negative for the Group. Profit before tax was NOK 261 million (NOK 292 million). Earnings per share were NOK 2.01 (NOK 2.32). - We are pleased with the strong result improvement in BioSolutions and the positive sales volume development for the Group, says President and CEO Per A. Sørlie. Contacts: Director Investor Relations, Knut-Harald Bakke, +47 905 79 164 Director Communicat
[Ad hoc announcement pursuant to Art. 53 LR] Roche sales increase by 2% (CER) in first quarter with both divisions growing in high single digit ex COVID-1924.4.2024 07:00:00 CEST | Press release
Group sales grew by 2%1 at constant exchange rates (CER) (-6% in CHF), driven by the strong growth of newer medicines and diagnostics. Excluding COVID-19-related products, sales increased by 7%. Going forward, there will be no further material impact of COVID-19 sales declineDue to the appratioss fn of the Swiranc against most currencies, sales were 6% lower when reported in CHFPharmaceuticals Divisionbase business2 grew by 7%, driven by strong sales of medicines to treat severe diseases, such as Vabysmo (eye diseases), Phesgo (breast cancer), Ocrevus (multiple sclerosis), Polivy (blood cancer) and Hemlibra (haemophilia A). Divisional sales growth was 2%, reflecting the impact of the expected decline in sales of the COVID-19 medicine Ronapreve Diagnostics Division base business2 grew by 8%, supported by growth across all regions because of demand for immunodiagnostic products, clinical chemistry tests and advanced staining solutions. As this growth was partially offset by the lower dem